News

“This past year was pivotal for Sequenom as we continued to advance our genetic analysis and molecular diagnostics businesses,” stated Harry Stylli, president and chief executive officer of

As a result of the court’s decision, Par will accrue additional reserves of approximately $28 million on an after-tax basis in the fourth quarter of 2008. Par and

As part of the transaction, Allscripts intends to continue to offer medication services to existing and future clients of Allscripts under a co-marketing agreement. Closing of the transaction

According to QuantRx, this new patent for oral testing devices expands the company’s protection, and will allow it to bring its ultrasensitive RapidSense technology to address the point-of-care

Chest-1 is a Phase III multi-center, double-blind, randomized, placebo-controlled trial in patients with inoperable chronic thromboembolic pulmonary hypertension. The trial will involve 270 patients who will be randomized

The company announced revenues of $17.2 million for the quarter ended December 31, 2008. This compares to revenues of $19.8 million for the quarter ended December 31, 2007.

The FDA approval is based on results from a multicenter study comparing catheter ablation to drug therapy for the treatment of atrial fibrillation (AFib). In this randomized clinical

Until a permanent successor is appointed, Mr Martin will assume the responsibilities formerly held by John Ahern. Mr Ahern has announced his retirement and has also resigned from

Dr Cope has most recently served as the assistant director for research and head of program research development for The Ohio State University Comprehensive Cancer Center, The James